|
|
Volumn 20, Issue 9, 2012, Pages 2982-2991
|
|
Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators
a
a
a
a
a
|
|
Author keywords
Aminothiazole; Benzamide derivatives; Glucokinase activator; Privileged fragment merging; Type 2 diabetes (T2D)
|
|
Indexed keywords
3 [(3 METHYLBUT 2 EN 1 YL)OXY] 5 [4 (MORPHOLINOSULFONYL)PHENOXY] N (THIAZOL 2 YL)BENZAMIDE;
3 [4 (8 OXA 3 AZABICYCLO[3.2.1]OCTAN 3 YLSULFONYL)PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY] N (THIAZOL 2 YL)BENZAMIDE;
3 [4 (8 OXA 3 AZABICYCLO[3.2.1]OCTAN 3 YLSULFONYL)PHENOXY] N (1 METHYL 1H PYRAZOL 3 YL) 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 (8 OXA 3 AZABICYCLO[3.2.1]OCTAN 3 YLSULFONYL)PHENOXY] N (1,5 DIMETHYL 1H PYRAZOL 3 YL) 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 (8 OXA 3 AZABICYCLO[3.2.1]OCTAN 3 YLSULFONYL)PHENOXY] N (5 FLUOROTHIAZOL 2 YL) 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 (CYCLOPROPYLSULFONYL)PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY] N (4 OXO 4,5 DIHYDROTHIAZOL 2 YL)BENZAMIDE;
3 [4 (CYCLOPROPYLSULFONYL)PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY] N (5 METHYLPYRAZIN 2 YL)BENZAMIDE;
3 [4 (CYCLOPROPYLSULFONYL)PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY] N (THIAZOL 2 YL)BENZAMIDE;
3 [4 (CYCLOPROPYLSULFONYL)PHENOXY] N (1 METHYL 1H PYRAZOL 3 YL) 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 (CYCLOPROPYLSULFONYL)PHENOXY] N (1,5 DIMETHYL 1H PYRAZOL 3 YL) 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 (CYCLOPROPYLSULFONYL)PHENOXY] N (5 FLUOROTHIAZOL 2 YL) 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 (CYCLOPROPYLSULFONYL)PHENOXY] N (IMIDAZO[1,2 A]PYRAZIN 8 YL) 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 (CYCLOPROPYLSULFONYL)PHENOXY] N [4 (4 FLUOROPHENYL)THIAZOL 2 YL] 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 [(2,6 DIMETHYLMORPHOLINO)SULFONYL]PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY] N (THIAZOL 2 YL)BENZAMIDE;
3 [4 [(2,6 DIMETHYLMORPHOLINO)SULFONYL]PHENOXY] N (1 METHYL 1H PYRAZOL 3 YL) 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 [(2,6 DIMETHYLMORPHOLINO)SULFONYL]PHENOXY] N (5 FLUOROTHIAZOL 2 YL) 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 [(3 FLUOROPYRROLIDIN 1 YL)SULFONYL]PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY] N (THIAZOL 2 YL)BENZAMIDE;
3 [4 [(3 FLUOROPYRROLIDIN 1 YL)SULFONYL]PHENOXY] N (5 FLUOROTHIAZOL 2 YL) 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
3 [4 [(4 METHOXYPIPERIDIN 1 YL)SULFONYL]PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY] N (THIAZOL 2 YL)BENZAMIDE;
BENZAMIDE DERIVATIVE;
ENZYME ACTIVATOR;
GK 50;
N (1 METHYL 1H PYRAZOL 3 YL) 3 [(3 METHYLBUT 2 EN 1 YL)OXY] 5 [4 (MORPHOLINOSULFONYL)PHENOXY]BENZAMIDE;
N (1,5 DIMETHYL 1H PYRAZOL 3 YL) 3 [(3 METHYLBUT 2 EN 1 YL)OXY] 5 [4 (MORPHOLINOSULFONYL)PHENOXY]BENZAMIDE;
N (1,5 DIMETHYL 1H PYRAZOL 3 YL) 3 [4 [(2,6 DIMETHYLMORPHOLINO)SULFONYL]PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
N (1,5 DIMETHYL 1H PYRAZOL 3 YL) 3 [4 [(3 FLUOROPYRROLIDIN 1 YL)SULFONYL]PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
N (5 FLUOROTHIAZOL 2 YL) 3 [(3 METHYLBUT 2 EN 1 YL)OXY] 5 [4 (MORPHOLINOSULFONYL)PHENOXY]BENZAMIDE;
N (5 FLUOROTHIAZOL 2 YL) 3 [4 [(4 METHOXYPIPERIDIN 1 YL)SULFONYL]PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
N [4 (TERT BUTYL)THIAZOL 2 YL] 3 [4 (CYCLOPROPYLSULFONYL)PHENOXY] 5 [(3 METHYLBUT 2 EN 1 YL)OXY]BENZAMIDE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ANIMAL EXPERIMENT;
ANTIDIABETIC ACTIVITY;
AREA UNDER THE CURVE;
ARTICLE;
CONCENTRATION RESPONSE;
CONTROLLED STUDY;
DISTRIBUTION VOLUME;
DRUG ACTIVATION;
DRUG BINDING;
DRUG BIOAVAILABILITY;
DRUG CLEARANCE;
DRUG DESIGN;
DRUG HALF LIFE;
DRUG IDENTIFICATION;
DRUG POTENCY;
DRUG SCREENING;
DRUG STRUCTURE;
DRUG SYNTHESIS;
ENZYME ACTIVITY;
GLUCOSE BLOOD LEVEL;
HUMAN;
IN VITRO STUDY;
IN VIVO STUDY;
MALE;
MAXIMUM PLASMA CONCENTRATION;
MOUSE;
NONHUMAN;
PLASMA CLEARANCE;
SINGLE DRUG DOSE;
STRUCTURE ACTIVITY RELATION;
SUBSTITUTION REACTION;
TIME TO MAXIMUM PLASMA CONCENTRATION;
ANIMALS;
BENZAMIDES;
BIOLOGICAL AVAILABILITY;
DRUG DESIGN;
ENZYME ACTIVATION;
GLUCOKINASE;
HYPOGLYCEMIC AGENTS;
MICE;
MICE, INBRED ICR;
STRUCTURE-ACTIVITY RELATIONSHIP;
THIAZOLES;
MUS;
|
|
EID: 84862819984
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2012.03.008 Document Type: Article |
|
Times cited : (50)
|
|
References (42)
|
